ReturnScreener

Rolling Returns

JBCHEPHARM Rolling Returns

J.B. Chemicals & Pharmaceuticals Ltd.

Every 15-year stretch JBCHEPHARM has been through — 60 of them, each starting a month after the last. The median returned 31.9% a year, the worst 26.1%, the best 41.5%. A single headline CAGR hides all of that.

Windows measured
60
Median
31.9%
Worst
26.1%
Best
41.5%

Every Holding Period

JBCHEPHARM rolling returns by holding period

A rolling window is every possible start date, not one. A five-year window starting in January is a different investment from one starting in February, and over twenty years there are a couple of hundred of them. What follows is the full spread of what each holding period actually produced.

1-year rolling returns

74.6% of windows made money

Across 228 separate 1-year holding periods, the median returned 29.2% a year. The worst lost 50.0% a year and the best made 201.6%.

-50.0%median 29.2%201.6%
Worst window
-50.0%
25th percentile
-0.5%
75th percentile
62.5%
Best window
201.6%

Worst start: September 2007-50.0% a year for the 1 years that followed.

Best start: October 2019201.6% a year.

Against the Nifty 500: JBCHEPHARM came out ahead in 71.5% of the 228 windows both series cover.

3-year rolling returns

95.6% of windows made money

Across 204 separate 3-year holding periods, the median returned 29.8% a year. The worst lost 17.6% a year and the best made 90.8%.

-17.6%median 29.8%90.8%
Worst window
-17.6%
25th percentile
16.7%
75th percentile
51.3%
Best window
90.8%

Worst start: October 2006-17.6% a year for the 3 years that followed.

Best start: July 201890.8% a year.

Against the Nifty 500: JBCHEPHARM came out ahead in 85.8% of the 204 windows both series cover.

5-year rolling returns

100.0% of windows made money

Across 180 separate 5-year holding periods, the median returned 34.3% a year. Not one of them ended in a loss — the weakest still compounded at 1.1% a year.

1.1%median 34.3%64.8%
Worst window
1.1%
25th percentile
24.6%
75th percentile
43.3%
Best window
64.8%

Worst start: January 20071.1% a year for the 5 years that followed.

Best start: October 201964.8% a year.

Against the Nifty 500: JBCHEPHARM came out ahead in 96.7% of the 180 windows both series cover.

7-year rolling returns

100.0% of windows made money

Across 156 separate 7-year holding periods, the median returned 36.7% a year. Not one of them ended in a loss — the weakest still compounded at 5.6% a year.

5.6%median 36.7%47.7%
Worst window
5.6%
25th percentile
27.4%
75th percentile
41.4%
Best window
47.7%

Worst start: August 20065.6% a year for the 7 years that followed.

Best start: August 201747.7% a year.

Against the Nifty 500: JBCHEPHARM came out ahead in 99.4% of the 156 windows both series cover.

10-year rolling returns

100.0% of windows made money

Across 120 separate 10-year holding periods, the median returned 32.1% a year. Not one of them ended in a loss — the weakest still compounded at 19.6% a year.

19.6%median 32.1%44.9%
Worst window
19.6%
25th percentile
28.8%
75th percentile
39.5%
Best window
44.9%

Worst start: January 200719.6% a year for the 10 years that followed.

Best start: September 201344.9% a year.

Against the Nifty 500: JBCHEPHARM came out ahead in 100.0% of the 120 windows both series cover.

15-year rolling returns

100.0% of windows made money

Across 60 separate 15-year holding periods, the median returned 31.9% a year. Not one of them ended in a loss — the weakest still compounded at 26.1% a year.

26.1%median 31.9%41.5%
Worst window
26.1%
25th percentile
29.5%
75th percentile
37.4%
Best window
41.5%

Worst start: January 200726.1% a year for the 15 years that followed.

Best start: April 200941.5% a year.

Against the Nifty 500: JBCHEPHARM came out ahead in 100.0% of the 60 windows both series cover.

Windows step forward one month at a time and are measured on month-end adjusted closing prices, so dividends are treated as reinvested. Overlapping windows share months by construction — that is what makes the spread a description of this stock's history rather than a sample of independent trials.

Against The Index

How often JBCHEPHARM beat the Nifty 500

Beating an index once is a result. Beating it across most of the periods an investor could have picked is a pattern. Over 15-year windows, JBCHEPHARM finished ahead of the Nifty 500 in 100.0% of the 60 periods both series cover.

1-year windows

Ahead in 71.5% of 228 periods.

3-year windows

Ahead in 85.8% of 204 periods.

5-year windows

Ahead in 96.7% of 180 periods.

7-year windows

Ahead in 99.4% of 156 periods.

10-year windows

Ahead in 100.0% of 120 periods.

15-year windows

Ahead in 100.0% of 60 periods.

Each window is compared against the index over the identical calendar months, on the same adjusted basis — not against an assumed rate of return.

How This Is Calculated

Reading these figures properly

Overlapping by design

Windows step forward one month at a time, so they share most of their months with each other. That is what makes this a description of JBCHEPHARM's actual history rather than a set of independent trials — and why the spread should not be read as a probability.

Month-end, total return

Measured on month-end closing prices adjusted for dividends and splits, so dividends count as reinvested. A window that opened or closed mid-month would differ a little in either direction.

Survivors only

JBCHEPHARMis in today's Nifty 500 universe. Companies that delisted or collapsed are not on this site at all, so the worst outcome shown here is the worst among the survivors.

Measured on data to 2026-07-31, from 2006-08-01. Full definitions are on our methodology page.

HELP CENTER

JBCHEPHARM rolling returns — common questions

Everything you need to know about this page and the data presented.

What are JBCHEPHARM rolling returns?
+

Over 15 years, J.B. Chemicals & Pharmaceuticals Ltd. has been through 60 separate 15 years holding periods — one starting every month. The median returned 31.9% a year, the worst 26.1% and the best 41.5%. A rolling return measures every possible start date instead of one, which is why it answers a question a single headline CAGR cannot: how much the outcome depended on when you happened to buy.

Has JBCHEPHARM ever lost money over 10 years?
+

No — not in any of the 120 10 years periods the record covers. The weakest of them still compounded at 19.6% a year. That is a statement about the past, not a guarantee about any future 10 years, and it is measured only over the years J.B. Chemicals & Pharmaceuticals Ltd. has been listed.

What is the worst 5 years JBCHEPHARM has ever had?
+

1.1% a year, for the five years beginning January 2007. For contrast the best 5 years returned 64.8% a year, starting October 2019, and the median across all 180 periods was 34.3%. The gap between those two numbers is the part of the outcome that came down to timing rather than to the company.

Does holding JBCHEPHARM for longer reduce the risk?
+

On this record, yes. 1 year outcomes ranged from -50.0% to 201.6% a year — a spread of 251.6%. 15 years outcomes ranged from 26.1% to 41.5%, a spread of 15.4%. Longer holding periods narrowed the range of results, which is the usual pattern and the reason this page publishes every window rather than one. Narrowing the range is not the same as removing the risk.

How often has JBCHEPHARM beaten Nifty 500 over 15 years?
+

In 100.0% of the 60 15 years periods both series cover. Each window is compared against the index over the identical months, not against an assumed index return, so the comparison is a like-for-like record rather than a model.

How are rolling returns calculated here?
+

Windows step forward one month at a time on month-end closing prices adjusted for dividends and stock splits, so dividends are treated as reinvested. A window length is only published once there are at least twelve complete windows behind it — fewer than that describes an anecdote, not a distribution. Overlapping windows share months by construction, which is what makes this a description of the actual history of J.B. Chemicals & Pharmaceuticals Ltd. rather than a sample of independent trials. Companies that delisted are not on this site at all, a survivorship bias worth holding in mind.

Is JBCHEPHARM a safe long-term investment?
+

That is not a question this page answers, and we do not make recommendations. What it can show you is the full range of what every holding period in the listed history of J.B. Chemicals & Pharmaceuticals Ltd. actually produced — including the worst ones, which most performance figures leave out. Those are records of what happened, not forecasts. A stock that never had a losing decade may still have one, and holding a single company is a materially different risk from holding an index.

Explore Further

More on J.B. Chemicals & Pharmaceuticals Ltd.

ReturnScreener is an educational research platform and is not a SEBI-registered investment adviser. Everything on this page is a record of what historical prices did, not a projection and not a recommendation. Past performance does not guarantee future returns. See our methodology and disclaimer.